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Perivascular delivery of antiproliferative drugs has been
proposed as an approach to prevent neointimal hyperplasia
associated with hemodialysis polytetrafluoroethylene (PTFE)
grafts. We examined this approach to deliver dipyridamole in
a porcine graft model. PTFE grafts were implanted between
the carotid artery and external jugular vein bilaterally in pigs.
During the surgery or 1 week post-graft placement,
dipyridamole (0.26–52 mg) alone or incorporated in
microspheres was mixed with an injectable polymeric gel and
applied to the graft-arterial and graft-venous anastomoses
on one side, whereas the contralateral control graft received
no treatment. Three or four weeks after operation, the grafts
and adjacent vessels were explanted en bloc and cross-
sections of the anastomoses were examined histologically.
The degree of neointimal hyperplasia was quantified by
planimetry. In separate experiments, dipyridamole was
extracted from the explanted tissues and assayed by
spectrofluorometry. The normalized median hyperplasia
areas of the treated and control graft-venous anastomoses
were 0.45 (25th–75th percentile, 0.30–0.86) and 0.24
(0.21–0.30), respectively (N¼ 7; P¼ 0.08). The median
hyperplasia areas of the treated and control graft-arterial
anastomoses were 0.12 (0.07–0.39) and 0.11 (0.09–0.13),
respectively (N¼ 7; P¼ 0.31). The dipyridamole levels in the
vascular walls around the anastomoses were at or above the
in vitro inhibitory concentrations for approximately 3 weeks.
These results suggest that the local perivascular sustained
delivery of dipyridamole, even at high dosages, was
ineffective in inhibiting neointimal hyperplasia associated
with PTFE grafts in a porcine model.
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Stenosis followed by thrombosis is the major cause of failure
of polytetrafluoroethylene (PTFE) grafts for chronic hemo-
dialysis. Stenosis occurs most commonly at the graft-venous
anastomosis, although the graft-arterial anastomosis is
also affected.1 Histologically, the lesions consist mostly of
myointimal hyperplasia, which is composed of proliferating
vascular smooth muscle cells, extracellular matrix, and
neo-microvasculature.2 Therefore, the inhibition of smooth
muscle cell proliferation and migration would appear to be
a reasonable approach to prevent graft stenosis. Although
the pathogenesis of neointimal hyperplasia associated with
dialysis grafts has not been fully elucidated, a number of
contributing factors are probably operative on a chronic
basis, beyond the initial surgical trauma. These include the
mismatch of vessel sizes and compliance, localized flow
disturbances, and the release of growth factors from the
vascular wall and adhering platelets in response to dialysis
needle puncture. Therefore, chronic rather than acute
delivery of antiproliferative agents is likely to be necessary
to prevent stenosis on a long-term basis.
Dipyridamole is an antiproliferative drug with a primary
mechanism of action thought to derive from inhibiting
phosphodiesterases and subsequently increasing intracellular
cyclic nucleotide levels.3 One clinical study has suggested that
daily oral dipyridamole with or without aspirin decreased the
incidence of graft occlusion in dialysis patients, although the
inhibition of neointimal hyperplasia was not documented.4
In addition, the number of patients studied was small (o30
in each group). A large multicenter trial sponsored by the
National Institutes of Health examining the efficacy of the
oral combination of dipyridamole and aspirin in maintaining
dialysis PTFE graft patency is ongoing.5
Because of the focal, superficial, and accessible nature of
the hyperplastic lesion associated with dialysis grafts, direct
application of an antiproliferative agent that produces high
local concentrations and minimal systemic exposure is an
attractive therapeutic strategy. In fact, systemic administra-
tion of dipyridamole has been found to be ineffective
in preventing the development of neointimal hyperplasia
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following interposition venous grafts to the femoral artery in
the dog6 and interposition PTFE grafts in the aorta in the
goat.7 In contrast, continuous infusion of dipyridamole into
the adventitia for more than 2 weeks was successful in partially
inhibiting intimal thickening after balloon injury in the carotid
or femoral artery of the rabbit.8 This latter study suggests that
the continuous local perivascular delivery of dipyridamole may
be more efficacious than systemic administration.
Our recent study has suggested that the local sustained
delivery of the antiproliferative drug paclitaxel using an
injectable polymeric gel (ReGels; see details in the Materials
and Methods section) applied perivascularly was effective
in inhibiting the neointimal hyperplasia at the graft
anastomoses in a canine model.9 These promising data, in
conjunction with the demonstration of greater potency of
dipyridamole in inhibiting the proliferation of cultured
vascular smooth muscle cells compared to paclitaxel,10 have
led to the present study. We report herein the results of
perivascular sustained delivery of dipyridamole in a porcine
model of PTFE graft stenosis.
RESULTS
Establishment of porcine PTFE model of stenosis
Eleven pigs with bilateral graft placement without drug
treatment were used to study the time-dependent progression
of neointimal hyperplasia. Two of these animals died within
24 h after surgery from complications of anesthesia. The
remaining nine animals were killed at 7 (n¼ 1), 14 (n¼ 2),
21 (n¼ 2), or 28 days (n¼ 4), respectively. No neointimal
hyperplasia was found within 7 days of graft placement,
whereas progressive hyperplasia was found after 14 days at
the graft-venous (Figure 1) and graft-arterial anastomoses
(not shown).
Assessment of neointimal hyperplasia
Nine pigs were used to examine the efficacy of local
dipyridamole treatment. In two of the nine animals, technical
problems prohibited comparison of the histology of the two
sides. Thus, these two animals were excluded from statistical
analysis. The degree of neointimal hyperplasia at each
anastomosis was evaluated by both visual scoring (range
0–5) and planimetry in the remaining seven animals. The
median hyperplasia score of the treated graft-venous
anastomoses was 3.0 (2.05–3.59), whereas the score of the
contralateral controls was 2.3 (1.85–2.45; N¼ 7; P¼ 0.08;
Figure 2a). The median hyperplasia surface area of the treated
graft-venous anastomoses quantified by planimetry, normal-
ized to the cross-sectional surface area of the graft, was 0.45
(0.30–0.86). For the controls, it was 0.24 (0.21–0.30; N¼ 7;
P¼ 0.08 (Figure 2b)).
The median hyperplasia visual score of the treated graft-
arterial anastomoses was 1.40 (0.88–2.30), whereas the
median score of the contralateral controls was 1.65
(1.25–2.05; N¼ 7; P¼ 0.64; Figure 3a). The median normal-
ized hyperplasia area of the treated graft-arterial anastomoses
was 0.12 (0.07–0.39), whereas the median hyperplasia area
of the contralateral controls was 0.11 (0.09–0.13; N¼ 7;
P¼ 0.31; Figure 3b).
Local effects of drug depot
Local perivascular delivery of dipyridamole did not result in
any overt problems at the site of graft implantation. There
was no obvious bleeding from the surgical wound or delayed
wound healing. No inflammatory reactions were visible on or
through the skin. In four animals, however, histological
examination showed the drug depot to be encapsulated.
Figure 4 shows the hematoxylin and eosin (H&E) staining of
a cross-section of the graft-venous anastomosis from an
animal that received 52 mg of dipyridamole in microspheres/
ReGel intraoperatively and was killed 28 days later. The
section clearly shows that the depot remained at the site of
deposition near the anastomosis contiguous with the blood
vessel. Despite the conspicuous presence of the drug depot,
neointimal hyperplasia was readily seen in the adjacent
lumen. Closer examination under high magnification shows
that the depot was surrounded by a septated fibrous capsule
(Figure 4, inset), which was confirmed by trichrome staining.
Occasional giant cells were seen inside the capsule. The
encapsulation was also found on histological examination
in three other pigs treated with dipyridamole delivered by
microspheres/ReGel.
Target tissue concentrations of dipyridamole
High concentrations of dipyridamole were found in the
arterial and venous wall at the anastomoses (Figure 5),
indicating that the drug released from microspheres/ReGel
readily diffused into the target sites. The mean concentrations
remained above 100 mg/ml for at least 8 days and decreased to
approximately 10 mg/ml by 21 days at both arterial and
venous anastomoses.
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Figure 1 | Histologic appearance of neointimal hyperplasia at the
graft-venous anastomosis at different time points. The tissue
cross-sections were obtained as described in Figure 7 (cross-section
D) and stained with H&E and examined at original magnification,  5.
Neointimal hyperplasia (NH) was minimal at the graft-venous
anastomosis at (a) 14 days and progressive at (b) 21 and (c) 28 days
post-graft placement.
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Systemic effects of locally delivered dipyridamole
There were no noticeable physical problems, such as
generalized or localized bleeding, in the treated animals. All
complete blood counts and blood chemistries were within the
normal range. Peripheral plasma dipyridamole concentra-
tions were consistently below the detection limit of 10 ng/ml
at all time points.
DISCUSSION
Because of the chronic nature of the stimuli, long-term
preservation of dialysis PTFE grafts likely requires the
sustained delivery of antiproliferative agents. Although daily
oral administration is a possibility, local delivery of agents
targeting the likely foci of hyperplasia development allows far
higher local drug concentrations while minimizing systemic
side effects. There are a variety of techniques for local drug
delivery, including the coating of the graft or intraluminal
stent with antiproliferative agents. The latter approach
requires an invasive procedure and the lodging of an
additional foreign object, with the associated risks of further
endothelial injury, thrombosis, and infection. Neither
technique permits the replenishment of the antiproliferative
agent. In contrast, the percutaneous injection of a sustained-
delivery platform would allow for the repeated replenishment
of the drug depot at the superficial perivascular locations.
The thermosensitive triblock polymer ReGel appears to fulfill
these requirements.11 Indeed, our recent study suggests that
the delivery of paclitaxel using this system was effective in
inhibiting neointimal hyperplasia in a canine model.9
Although ReGel can solubilize and stabilize a variety
of substances, hydrophilic drugs such as dipyridamole are
usually retained for shorter durations in the gel than those
with greater hydrophobicity. The incorporation of dipyrida-
mole into polymeric microspheres before mixing with ReGel
substantially decreased the initial burst and extended its
release.12 This combination was therefore used to provide
injectable, sustained delivery of dipyridamole in our porcine
model.
A large number of substances have been reported to
possess antiproliferative properties against arterial smooth
muscle cells, although their efficacies against venous smooth
muscle cells have not been extensively tested.10 If effective,
the use of small-molecule drugs is probably simpler, safer,
and less expensive than biological reagents, such as antibodies
and oligodeoxynucleotides. Our selection of dipyridamole in
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Figure 2 | Effect of local delivery of dipyridamole on neointimal
hyperplasia at graft-venous anastomoses. Dipyridamole was
delivered using microspheres/ReGel or ReGel alone as a perivascular
sustained-release depot around the graft-venous and graft-arterial
anastomoses as described in Table 1. The degree of neointimal
hyperplasia was assessed by (a) visual scoring (scale of 0–5, with 5
representing maximal hyperplasia) and (b) by planimetry. The
planimetry results are presented as the ratio of the cross-sectional
surface area of the hyperplastic tissue, normalized to the cross-
sectional surface area of the graft, resulting in a dimensionless value.
The thin lines connecting the control and dipyridamole-treated
values represent individual animals, whereas the thick line
represents the median value of all animals. There were no statistically
significant differences between the mean control values and the
dipyridamole-treated values as assessed by either scoring (N¼ 7;
P¼ 0.08) or planimetry (N¼ 7; P¼ 0.08).
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Figure 3 | Effect of local delivery of dipyridamole on neointimal
hyperplasia at graft-arterial anastomoses. The methods of drug
administration and assessment of hyperplasia are similar to those
described in Figure 2. (a) Results of visual scoring. (b) Results by
planimetry. There were no statistically significant differences between
the median control values and the dipyridamole-treated values at the
graft-arterial anastomoses as assessed by either scoring (N¼ 7;
P¼ 0.64) or planimetry (N¼ 7; P¼ 0.31).
Figure 4 | Histologic examination of a drug depot at the graft-
vein anastomosis. Presented is the histologic cross-section stained
with H&E at the graft-venous anastomosis of a graft that received
dipyridamole in microspheres/ReGel intraoperatively and explanted
after 28 days. The original magnification of the main figure is  1.
The drug depot was encapsulated with fibrous tissues, which was
confirmed using trichrome staining (not shown). The inset (original
magnification,  20) is an enlargement of a segment of the depot,
showing fibrous tissues surrounding the microspheres, infiltrated by
mononuclear cells and giant cells (black arrow).
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testing the ReGel system is based on previous in vitro and in
vivo results. In vitro, dipyridamole markedly inhibits the
proliferation of both human arterial and venous smooth
muscle cells,8,13 with potency greater than that of paclitaxel.10
We also found that dipyridamole inhibited the proliferation
of porcine arterial and venous smooth muscle cells, with
potencies similar to those in human vascular smooth muscle
cells (unpublished data). In addition, venous smooth muscle
cells were more sensitive to dipyridamole than arterial
cells, for both human10 and porcine cells. The IC50 values
(concentrations required to inhibit cell proliferation by 50%)
were 12.771.6 and 16.671.0 mg/ml for porcine venous and
arterial cells, respectively (unpublished data). This observa-
tion is significant as neointimal hyperplasia occurs more
commonly at the venous anastomosis than the arterial
anastomosis of the arteriovenous graft. Not only does
dipyridamole inhibit the proliferation of normal human
and porcine cells,8,13 but is also effective in vitro against
vascular smooth muscle cells obtained from the hyperplastic
lesions in our porcine model (unpublished data). In a rabbit
model, the continuous infusion of dipyridamole into the
adventitia for more than 2 weeks partially inhibited intimal
thickening after balloon injury of the carotid artery,
providing further impetus to test this apparently promising
drug in a perivascular delivery model.8 It should also be
further noted that dipyridamole provides certain technical
advantages for in vivo pharmacokinetic analysis of a new
drug delivery system in that it is fluorescent and can be
readily detected in blood and tissue samples.
Despite the proper localization of ReGel around the
anastomoses (Figure 4), the perivascular delivery of dipyr-
idamole using this system failed to prevent neointimal
hyperplasia. In fact, there was a trend towards more severe
hyperplasia at the graft-venous anastomosis associated with
dipyridamole treatment, compared to untreated controls
(Figure 2). These results were consistent using either the
visual scoring or planimetry technique for analysis. The
explanations for this lack of efficacy are not apparent. Our
pharmacokinetic results in vitro and ex vivo have shown that
dipyridamole readily diffuses into and through the wall of the
PTFE graft, native porcine artery, and native porcine vein.14
The present study also demonstrated the presence of
significant concentrations of dipyridamole in the venous
and arterial walls around the anastomoses (Figure 5). These
tissue concentrations were 10- to 20-fold higher than the
in vitro IC50 values for porcine vascular smooth muscle cells
and decreased to IC50 values by 3 weeks. Thus, these
pharmacokinetic data suggest that the antiproliferative effects
of dipyridamole should have been exerted on the neointima
for most of the study period.
One potential explanation for the lack of efficacy in the
animal model is that the cell culture conditions used to
characterize antiproliferative effects of dipyridamole do not
properly mimic conditions in vivo, which is always a consi-
deration in extending in vitro results to in vivo applications.
For instance, neointimal cells in vivo may be exposed to high
concentrations of nitric oxide produced by inflammatory
cells or damaged endothelium. This might result in the
activation of guanylyl cyclase to produce high, sustained
intracellular concentrations of cGMP in neointimal cells,
comparable to concentrations achieved in vitro as a result
of phosphodiesterase inhibition by dipyridamole. It is also
possible that neointimal cells in vivo are exposed to a milieu
of mitogenic stimuli that are very different from that
encountered by cells in vitro and that the activation of these
different mitogenic signaling pathways is largely insensitive to
the antiproliferative effects of dipyridamole.
Local delivery of dipyridamole using microspheres and
ReGel appeared to be safe, even up to 104 mg per animal. No
systemic bleeding or other adverse effects were noted. This is
perhaps not surprising considering the slow release of the
total amount of drug over 3 weeks, in conjunction with the
hepatic metabolism of the drug. These resulted in no
detectable drug level in the peripheral blood throughout
the study period, in contrast to the usual clinical dose of
300 mg/day orally, which results in much higher systemic
concentrations. There were also no adverse events, such as
bleeding or delayed healing around the surgical wound. There
was, however, an apparent foreign body reaction to the drug
depot in four of the nine animals (44%), characterized by the
presence of mononuclear cell and giant cell infiltration as
well as fibrous capsule formation. Although it is difficult to
ascertain the exact culprit responsible for this reaction, the
administration of ReGel into rodents11 and dogs9 has not
produced significant local inflammatory responses. In
contrast, the administration of poly(lactide-co-glycolide)
microspheres with diameters o10 mm15 subcutaneously into
rats has been reported to produce similar reactions. We also
found similar reactions histologically in pigs after the
perivascular administration of ReGel mixed with micro-
spheres and without dipyridamole (unpublished data). Thus,
it is highly likely that these foreign body reactions observed in
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Figure 5 | Time-dependent changes in dipyridamole concentra-
tions in venous and arterial walls at graft anastomoses.
Dipyridamole (52 mg) was delivered using microspheres/ReGel as a
perivascular sustained-release depot around the graft-venous and
graft-arterial anastomoses. The graft and adjoining native vessels
were explanted at the indicated time points after graft placement.
Dipyridamole was extracted from the venous wall (a) and the arterial
wall (b) and assayed. N¼ 3 at 0.5, 1.5, 4, and 8 days and N¼ 2 at
21 days.
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our present experiments were due to the presence of
microspheres. It should, however, be noted that this reaction
was seen in only a subset of animals tested. It is also likely
that the employment of fewer microspheres of larger sizes
may markedly diminish this reaction.15
There are limitations to the present study. First, aspirin
and clopidogrel were employed to prevent thrombosis in
order to study the development of neointimal hyperplasia,
similar to the porcine PTFE graft models reported by other
investigators.16–20 In addition to its anti-platelet effects,
aspirin has also been shown to potentiate the proliferation
of human vascular smooth muscle cells induced by platelet-
derived growth factor,21 which might have confounded the
results in the present study. Both control and experimental
grafts, however, were exposed to this drug, which was
administered systemically. Second, the animals in this and
other porcine models16–20 were normal rather than uremic.
As such, the pathophysiology of the hyperplasia and the
response to pharmacological treatment may potentially be
different from uremic animals.
Although this study showed the general utility of the
microsphere/ReGel system as a sustained local drug delivery
system, it is unlikely that dipyridamole will be effective
for the prevention of neointimal hyperplasia associated
with hemodialysis arteriovenous PTFE graft stenosis when
delivered in this manner. Other antiproliferative drugs with
different mechanisms of action, particularly those that are
more hydrophobic and thus can achieve longer sustained
release from ReGel, should be investigated.
MATERIALS AND METHODS
Preparation of dipyridamole-incorporated microspheres
ReGel (MacroMed Inc., Sandy, UT, USA) is a polymeric gel designed
for the sustained release of drugs. Because of its thermosensitive
nature, liquid ReGel can be mixed with drugs in vitro and injected
into the body, where it rapidly transforms into a semi-solid gel and
provides a sustained-release drug depot.11 Although ReGel can
solubilize and stabilize a large variety of drugs, the low hydro-
phobicity of dipyridamole may diminish the sustained-release
kinetics from the gel. In order to prolong the release, dipyridamole
was first incorporated into poly(lactide-co-glycolide) (Medisorbs,
lactide:glycolide 50:50 (v/v), Mn 28 500 Da, Alkermes Inc., Cam-
bridge, MA, USA) microspheres using an oil-in-water emulsion
method.12 The microspheres that were prepared in this manner were
approximately 2–10 mm in diameter. Considering that the initial
drug loading level was 30% (i.e., 30 mg dipyridamole per 70 mg
poly(lactide-co-glycolide)) and the encapsulation efficiency of
dipyridamole in the microspheres was 55.0%, the final preparation
used in animal experiments contained 52 mg of dipyridamole per
315 mg of microspheres.
Preparation of mixture of dipyridamole or dipyridamole/
microspheres with ReGel
Dipyridamole/microspheres were sterilized by gamma irradiation
(Isomedix Inc., Whippany, NJ, USA) using 60Co as irradiation
source at a dose of 15 kGy. Dipyridamole (26–52 mg) in micro-
spheres or dipyridamole (0.26–26 mg) alone was mixed with 2 ml of
ReGel and maintained at 41C until use.
Porcine graft model
A total of 29 pigs were used: 11 for establishing the model, nine for
examination of drug efficacy, and nine for determination of tissue
drug concentrations. The porcine model of PTFE graft was
established as follows. All animal procedures and care were
performed in accordance with the ‘Principles of Laboratory Animal
Care’ and the ‘Guidelines for the Care and Use of Laboratory
Animals’ (NIH Publication No. 85-23, revised 2001) and were
approved by the Institutional Animal Care and Use Committee of
the University of Utah and the Veterans Affairs Salt Lake City
Healthcare System. Yorkshire cross domestic swine, weighing
30.970.9 kg, were used. General anesthesia was induced using
xylazine (4 mg/kg), telazol (4 mg/kg), and ketamine (4 mg/kg). The
trachea was then intubated and general anesthesia was maintained
using 1.5–2.5% isoflurane. Sodium heparin (100 U/kg) was given as
a single intravenous bolus at the beginning of the surgery. Under
sterile conditions, expanded PTFE grafts (spiral re-enforced, 7-cm
length, 6-mm internal diameter; Bard Peripheral Vascular Inc.,
Tempe, AZ, USA) were placed between the common carotid artery
and ipsilateral external jugular vein bilaterally.
As this study specifically targeted neointimal hyperplasia,
adjunctive anti-platelet agents were used to minimize the risk of
thrombosis. Starting 6 days preoperatively, aspirin EC (Phamaceu-
tical Formulations, Edison, NJ, USA) at 81 mg/day was admini-
strated orally. Clopidogrel (Bristol-Myers Squibb, New York, NY,
USA) at 225 mg was added 1 day before surgery and continued at
75 mg/day postoperatively. Both anti-platelet agents were continued
until death occurred. Enrofloxacin (Baytril, Bayer, Pittsburgh, PA,
USA) was administrated subcutaneously at 5 mg/kg/day starting on
the day of surgery and was continued for 3 days. For ultrasound,
blood sampling, and postoperative injection of dipyridamole, the
animals were sedated using intramuscular ketamine, xylazine, and
telazol, each at 4 mg/kg.
Dipyridamole administration
In four animals, immediately after graft placement, a mixture of
dipyridamole (26–52 mg)/microspheres and ReGel (2 ml) was applied
intraoperatively to the external surface of each of the graft-venous and
graft-arterial anastomoses on one side of the animal (Figure 6). In
order to ensure that the drug depot was held in place at the
anastomoses before tissue in-growth, the surrounding tissues were
sutured before wound closure. The contralateral graft received no
treatment and served as control. In five other animals, 1 week after
graft placement, dipyridamole (0.26–26 mg) directly mixed with ReGel
(2 ml) was injected into the perivascular area around each anastomosis
using an 18-gauge needle and a 3-ml syringe under ultrasound
guidance (see Table 1) on one side of the animal. The contralateral
graft received no treatment and served as control. In all cases, the side
that received the drug was selected at random in a blinded manner.
See Table 1 for summary of dipyridamole administration.
Graft patency monitoring and blood sampling
Patency of grafts was monitored weekly using a Doppler ultrasound
(SonoSite, Bothell, WA, USA) and an L38/10-5 MHz transducer
(TITAN, Sonosite). Peripheral blood was obtained from an ear vein
weekly for complete blood count, chemistry, and dipyridamole
concentration.
Tissue processing for histology
At various time points after graft placement, the animals were killed
by an intravenous injection of pentobarbital (100 mg/kg) and the
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grafts were explanted en bloc along with a 2-cm-long segment of
the adjacent blood vessels. The explanted grafts were immediately
fixed in 10% buffered formalin and embedded in paraffin. Two
standardized cross-sections were cut at each anastomosis: one at
3 mm from the proximal edge and the other at 3 mm from the distal
edge (Figure 7). The slides were stained with H&E and trichrome as
indicated.
Assessment of neointimal hyperplasia by scoring
Each slide of the anastomotic cross-sections was evaluated for
neointimal hyperplasia in the graft using two different methods. The
first was standard visual scoring by four independent observers who
were blinded to the treatment that the particular graft received.9 The
scoring ranged from 0 to 5, with 0.5-unit increments. Any tissue in-
growth overlying the graft lumen was considered to be neointimal
hyperplasia, with minimal lining of the graft being 0.5 and total
occlusion of the lumen by hyperplasia arbitrarily scored as 5. An
exemplary slide was used to define the score of 0.5 before scoring
started.
Quantification of neointimal hyperplasia by planimetry
Digital images of the H&E-stained cross-sections of each graft-vessel
anastomosis were obtained at original magnification,  1 using
a CCD camera connected to a dissecting scope. The outline of the
hyperplastic tissue within the graft lumen on the computerized
images was determined by an independent blinded reviewer and the
surface area quantified using BioQuant Software (BioQuant Image
Analysis Corporation, Nashville, TN, USA).
Determination of tissue dipyridamole concentrations
In four pigs, a mixture of dipyridamole (52 mg)/microspheres and
ReGel (2 ml) was applied intraoperatively to the external surface of
each of the graft-venous and graft-arterial anastomoses on one side
of the animal. The contralateral (control) side received no
treatment. The animals were killed at 0.5, 1.5, 4, or 8 days after
graft implantation, respectively. As no dipyridamole (o10 ng/g)
could be detected in the vessel walls on the control side (i.e., there
was no transport of the drug from the other side), subsequent
experiments were performed in five additional pigs in which
bilateral grafts received a mixture of dipyridamole (52 mg)/micro-
spheres and ReGel (2 ml) at each anastomosis. These five animals
were killed at 0.5, 1.5, 4, 8, or 21 days after graft implantation,
respectively.
The graft along with the tissues between the two anastomoses
was explanted en bloc. The anastomoses were freed from
surrounding tissues by careful dissection. A 1-cm-long segment of
the native artery or vein immediately adjacent to the drug depot was
isolated and weighed. Dipyridamole was extracted from each section
by immersion into 1 ml of 100% ethanol. This vessel–ethanol
mixture was homogenized for 2 min on ice using a homogenizer
(PowerGen 700, Fischer Scientific, Pittsburg, PA, USA) and
centrifuged at 1500 r.p.m. for 10 min. The dipyridamole in the
supernatant was assayed using a spectrofluorometer at an excitation
wavelength of 412 nm and an emission wavelength of 495 nm.22 The
tissue drug amount was converted to concentrations assuming the
tissue density to be 1 g/cm3.
Determination of plasma dipyridamole concentrations
Systemic exposure to locally delivered dipyridamole was assessed by
determination of dipyridamole concentrations in peripheral blood.
Blood samples were obtained weekly from an ear vein. Plasma
concentrations of dipyridamole were measured as described above.
PTFE graft
Spiral
enforcement
Cephalad Caudal
Common
carotid artery
External
jugular vein
Figure 6 | Photograph of ReGel mixed with dipyridamole-
incorporated microspheres deposited at PTFE graft anastomoses.
An arteriovenous PTFE graft was created between the common
carotid artery and the external jugular vein. Liquid ReGel mixed with
dipyridamole-incorporated microspheres was applied to the
graft-arterial and the graft-veinous anastomoses (m). This liquid
transformed rapidly into a solid gel to provide a drug depot.
The yellow color of the gel was imparted by dipyridamole.
Table 1 | Dosage, time, and system for the local delivery of dipyridamole for individual animals
Animal no.
Time of dipyridamole
application Delivery system
Dose of dipyridamole
per anastomosis (mg)
Time of killing
(weeks)
1 1 week ReGel 0.26 3
2 1 week ReGel 0.26 3
3 1 week ReGel 2.6 3
4 1 week ReGel 2.6 3
5 1 week ReGel 26 3
6 Intraoperative ReGel+Msph 26 3
7 Intraoperative ReGel+Msph 52 4
8 Intraoperative ReGel+Msph 52 4
9 Intraoperative ReGel+Msph 52 4
The specified dosage of dypyridamole was mixed with 2 ml of ReGel and injected in liquid form under ultrasound guidance to the perivascular area surrounding each of the
venous and arterial anastomoses of one graft at 1 week (animal nos. 1–5) or incorporated into microspheres (Msph), mixed with 2 ml of ReGel and applied in gel form to the
perivascular surface of each of the venous and arterial anastomoses of one graft at the time of graft placement (animal nos. 6–9). The contralateral grafts received no
treatment and served as controls. Animal nos. 2 and 3 were excluded from statistical analysis of the hyperplasia because of technical problems. Bilateral grafts were patent at
the time of killing in all the remaining animals.
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Statistical analysis
Results of planimetry and visual scoring are expressed as the median
and the 25th and 75th percentile range. The Wilcoxon signed rank
test was used to compare the two groups. P-values o0.05 were
considered statistically significant.
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PTFE graft
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Cross-section
Figure 7 | Cross-sections of the graft-vessel anastomoses for
histologic analysis. Each graft-arterial or graft-veinous anastomosis
was cut along the two dotted lines to produce cross-sections for
histologic analysis of neointimal hyperplasia. The cross-section
designated ‘P’ was standardized at 3 mm from the proximal edge,
whereas the cross-section designated ‘D’ was standardized at 3 mm
from the distal edge of the anastomosis. NH, neointimal hyperplasia.
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